Roivant Sciences LTD

Roivant Sciences announced first-quarter 2026 financial results, highlighting strong progress in its drug development pipeline, including upcoming data readouts and a potential September 2026 launch for brepocitinib.

Roivant Sciences announced fourth quarter and fiscal year 2026 financial results, highlighting significant clinical trial progress and a major litigation settlement.

Roivant Sciences' subsidiary Genevant and Arbutus Biopharma reached a settlement with Moderna, resolving global patent litigation over mRNA vaccine technology for an initial $950 million and a potential $1.3 billion contingent payment.

Roivant Sciences' subsidiary, Genevant Sciences, and Arbutus Biopharma have reached a global settlement with Moderna for up to $2.25 billion over LNP technology patent infringement, alongside an increased $1 billion share repurchase program.

The U.S. Food and Drug Administration has accepted Priovant Therapeutics' New Drug Application for brepocitinib for dermatomyositis and granted it Priority Review, with a PDUFA target action date in Q3 2026.

Roivant Sciences announced positive Phase 2 results for brepocitinib in cutaneous sarcoidosis, alongside its Q3 2025 financial results and a significant Immunovant financing.

Roivant Sciences Ltd. filed its quarterly report for the period ended June 30, 2026, detailing a net loss of $290.6 million and increased operating expenses, while maintaining a substantial cash reserve of $3.8 billion.

Roivant Sciences reported a significant net loss for Q3 2025, driven by increased R&D and G&A expenses, despite a strong cash position and ongoing clinical pipeline progress.

Roivant Sciences Ltd. reported an increased net loss for the six months ended September 30, 2025, driven by higher R&D expenses and lower revenue, despite significant clinical trial advancements and a strong cash position.

Roivant Sciences reported a significant net loss from continuing operations in Q1 2025, driven by increased R&D and G&A expenses, while maintaining a strong cash position and advancing its diverse pipeline.

Roivant Sciences reports a net loss of $104.36 million for the nine months ended December 31, 2024, while strategically advancing its pipeline and completing the sale of Dermavant.

Roivant Sciences reported its second quarter 2024 results, showcasing a net loss but also highlighting strategic progress, pipeline advancements, and a strong cash position.

Roivant Sciences Ltd. filed its annual report detailing pipeline progress, financial performance, and strategic outlook, highlighting significant R&D investments and a strong cash position.

Roivant Sciences Ltd. reported a net loss of $356.7 million for fiscal year 2025, primarily due to increased operating expenses and the absence of a large one-time gain from the prior year's Telavant divestiture, despite significant clinical progress across its diverse biopharmaceutical pipeline.

Roivant Sciences Ltd. released its fiscal year 2024 results, showcasing significant revenue growth and strategic advancements, including the sale of Telavant to Roche for $7.1 billion.

Eric Venker, President & Immunovant CEO of Roivant Sciences Ltd., sold 200,000 shares of common stock on July 27, 2026 for $34.95 per share.

James C Momtazee, a Director of Roivant Sciences Ltd., received 405 shares of common stock on July 17, 2026.

Melissa B Epperly, a Director of Roivant Sciences Ltd., received 543 shares of common stock on July 17, 2026.

Ilan Oren, a Director of Roivant Sciences Ltd., received 775 shares of common stock on July 17, 2026.

Roivant Sciences CEO Matthew Gline reported a transaction involving the net settlement of Restricted Stock Units (RSUs) to cover tax obligations.

Meghan Fitzgerald, a Director at Roivant Sciences, reported transactions involving the acquisition and disposition of common shares and stock options.

Roivant Sciences Ltd. has issued its proxy statement for the 2026 Annual General Meeting of Shareholders, detailing proposals for director elections, auditor ratification, and executive compensation.

Roivant Sciences Ltd. has filed a Definitive Additional Materials proxy statement with the SEC.

Roivant Sciences Ltd. announced its 2025 Annual General Meeting to be held on September 10, 2025, where shareholders will vote on director elections, auditor ratification, and an advisory vote on executive compensation, alongside a review of fiscal year 2024 operational achievements.

Roivant Sciences Ltd. has filed a definitive proxy statement with the SEC.

Roivant Sciences Ltd. will hold its 2024 Annual General Meeting of Shareholders on September 10, 2024, to elect directors, ratify the appointment of Ernst & Young LLP, and conduct advisory votes on executive compensation.

Roivant Sciences Ltd. increased its beneficial ownership in Immunovant, Inc. to 55.9% by acquiring 16.67 million shares in a recent public offering.

Immunovant, Inc. announced the appointment of Eric Venker, M.D., President and Chief Operating Officer of Roivant Sciences, Inc., as its new Chief Executive Officer, effective April 21, 2025, as detailed in an amended Schedule 13D filing by major shareholder Roivant Sciences Ltd.

Roivant Sciences Ltd., a significant shareholder in Arbutus Biopharma Corp, has successfully orchestrated a complete change in Arbutus's Board of Directors, reducing its size and appointing new leadership, including a new CEO.

Roivant Sciences Ltd. has filed an Amendment No. 12 to its Schedule 13D, reaffirming its 20.5% beneficial ownership in Arbutus Biopharma Corp. and indicating potential near-term changes to the Issuer's board of directors and management.

Roivant Sciences Ltd. has increased its beneficial ownership in Immunovant, Inc. to 56.9% through a $337 million private placement, providing capital for Immunovant's development pipeline and general corporate purposes.

Morgan Stanley and its subsidiary, Morgan Stanley Investment Management Inc., have updated their Schedule 13G filing to reflect their beneficial ownership of Roivant Sciences Ltd. common shares.

Morgan Stanley and its subsidiary, Morgan Stanley Investment Management Inc., have filed a Schedule 13G, reporting beneficial ownership of Roivant Sciences Ltd. common shares.

Vivek Ramaswamy has filed an amendment to his Schedule 13G, reporting beneficial ownership of 25,534,970 common shares in Roivant Sciences Ltd.

The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in Roivant Sciences Ltd following an internal corporate realignment.

FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G, reporting a beneficial ownership of 10.3% of Roivant Sciences Ltd.'s common stock as of February 27, 2026.

Vivek Ramaswamy has increased his beneficial ownership in Roivant Sciences Ltd. to 6.8% of common shares, totaling 48,428,792 shares.